Taken together, our data identify the BRG1 BRD of SWI/SNF as a novel target in GBM and reveal the therapeutic potential of PFI-3 and other small molecules to inhibit SWI/SNF function to improve the clinical outcome of GBM. This evidence concerns the gene SMARCA1 and glioblastoma.